Figure 2b:

Graphs illustrate accuracy in diagnosing prostate cancer of stage T3a or higher with MR imaging or combined endorectal MR imaging–MR spectroscopic imaging (MRSI) in patients with clinical stage T1c disease. (a) Reader 1 had an AUC of 0.75 (95% CI: 0.65, 0.85) at endorectal MR imaging, with or without MR spectroscopic imaging. (b) Reader 2 had an AUC of 0.71 (95% CI: 0.61, 0.80) with use of MR imaging alone and 0.74 (95% CI: 0.65, 0.84) with use of combined MR imaging–MR spectroscopic imaging.